From the New York Times:
Stuart Miller, director of the International Tennis Federation’s antidoping program, approved Ms. Mattek-Sands’s applications for exemptions. He said that of the hundreds of applications he had approved in his 10-year tenure at the federation, hers were the only ones overruled by WADA.Dr. Rogol said DHEA, a precursor of testosterone, should never be approved for use by a female athlete.“It’s going to be turned, likely, into relatively small doses of testosterone, which of course for a woman, even small doses are performance enhancing,” Dr. Rogol said. “Women’s testosterone levels are normally perhaps a tenth of men’s, so if you boost them up to a fifth or a fourth of men’s, there likely will be an advantage.”Dr. Rogol called the Court of Arbitration’s expert “spot on” in his reasons for ultimately ruling against Ms. Mattek-Sands.“I think it tells you that tennis is a little bit more insular,” he said of the federation’s initial approval.